← Leaderboards
Michael Norman Krupp
Xfibra, Inc.
$967,440
Attributed
$2,902,320
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.5M · FY2019–20$2.5M$1.9M$1.3M$625K$0
'19
'20
Funding mix
By agency
NIH$2,902,320 · 2
By mechanism
R44$2,902,320 · 2
Top collaborators
- Martina Buck4 shared
- Mario Chojkier4 shared
Others in their field
Other Emerging Leaders on “Financial Hardship”
- Rishi Kumar Wadhera · Beth Israel Deaconess Medical Center$5,464,904
- Keith M Diaz · Columbia University Health Sciences$4,819,189
- Eugenia C South · University Of Pennsylvania$4,794,401
- Karen Marie Winkfield · Vanderbilt University Medical Center$3,863,636
- Victoria S Blinder · Sloan-Kettering Inst Can Research$3,601,187
- Laura Marianne Huckins · Yale University$3,567,684
Research focus
Financial HardshipLibrariesCicatrixFibrogenesisImmunogenicityIsoenzymesCellsChronicDrug KineticsFda ApprovedApoptosisFundingInflammationInjuryAnalogBiological AvailabilityAnimal ModelCellular TargetingDesignDoseAnimalsCardiotoxicityCasp8 GeneLiver
Grant awards (4)
TREATMENT OF LUNG FIBROSIS : IND PHARMACOLOGY AND TOXICOLOGY$1,326,982
R44 · FY2020 · HL
TREATMENT OF LIVER INJURY AND FIBROSIS: SAFETY PHARMACOLOGY AND TOXICOLOGY$1,136,111
R44 · FY2020 · DK · contact PI
TREATMENT OF LUNG FIBROSIS : IND PHARMACOLOGY AND TOXICOLOGY$224,967
R44 · FY2019 · HL · contact PI
TREATMENT OF LIVER INJURY AND FIBROSIS: SAFETY PHARMACOLOGY AND TOXICOLOGY$214,260
R44 · FY2019 · DK · contact PI